254 related articles for article (PubMed ID: 18485575)
1. Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
Martínez-García R; Abadías M; Arañó P; Perales L; Ruíz JL; Sust M; Conejero J;
Eur Urol; 2009 Jul; 56(1):184-90. PubMed ID: 18485575
[TBL] [Abstract][Full Text] [Related]
2. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
4. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
Nitti VW; Rovner ES; Bavendam T
BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
6. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
[TBL] [Abstract][Full Text] [Related]
7. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
[TBL] [Abstract][Full Text] [Related]
9. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
Marschall-Kehrel D; Feustel C; Persson de Geeter C; Stehr M; Radmayr C; Sillén U; Strugala G
Eur Urol; 2009 Mar; 55(3):729-36. PubMed ID: 18502028
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
Nitti VW; Dmochowski R; Sand PK; Forst HT; Haag-Molkenteller C; Massow U; Wang J; Brodsky M; Bavendam T
J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
[TBL] [Abstract][Full Text] [Related]
11. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
12. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
14. Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
May F; Bauer R
Eur Urol; 2009 Jul; 56(1):191. PubMed ID: 18485571
[No Abstract] [Full Text] [Related]
15. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
Wein AJ; Khullar V; Wang JT; Guan Z
BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
[TBL] [Abstract][Full Text] [Related]
16. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
Haab F; Stewart L; Dwyer P
Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
[TBL] [Abstract][Full Text] [Related]
17. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.
Ohlstein EH; von Keitz A; Michel MC
Eur Urol; 2012 Nov; 62(5):834-40. PubMed ID: 22695239
[TBL] [Abstract][Full Text] [Related]
19. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.
Staskin D; Khullar V; Michel MC; Morrow JD; Sun F; Guan Z; Dmochowski R
Neurourol Urodyn; 2011 Nov; 30(8):1480-5. PubMed ID: 21560158
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
Steers WD; Herschorn S; Kreder KJ; Moore K; Strohbehn K; Yalcin I; Bump RC;
BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
